Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals Inc. (ARWR) is a clinical-stage biotechnology leader developing RNA interference (RNAi) therapies that target disease-causing genes. This page provides investors and industry professionals with verified updates on the company's progress in advancing treatments for genetic disorders through its proprietary TRIM™ delivery platform.
Access consolidated, factual reporting of Arrowhead's material developments including clinical trial milestones, regulatory submissions, research collaborations, and financial disclosures. Our news aggregation ensures efficient tracking of therapeutic advancements in hepatitis B, cardiovascular diseases, and rare genetic conditions.
All content undergoes strict verification to maintain compliance with financial reporting standards. For stakeholders monitoring RNAi innovation and precision medicine breakthroughs, this resource offers centralized access to essential updates without speculative commentary.
Bookmark this page for streamlined monitoring of Arrowhead's progress in developing targeted gene silencing therapies. Check regularly for authoritative reporting on pipeline developments and strategic initiatives shaping the future of RNA-based medicine.
Arrowhead Pharmaceuticals presented Phase 2 data for its investigational drug plozasiran at the European Atherosclerosis Society 92nd Congress. The drug significantly reduced triglyceride levels in patients with mixed hyperlipidemia, showing reductions in APOC3, non-HDL-C, and remnant cholesterol. These results were also published in the New England Journal of Medicine. In the MUIR study, plozasiran achieved -50% to -62% reductions in triglycerides and normalization in up to 92% of patients. Significant reductions in other atherogenic lipoproteins were also observed. Plozasiran demonstrated a favorable safety profile with comparable treatment-emergent adverse events (TEAEs) to placebo. Arrowhead will continue to investigate the drug in Phase 3 studies.
Arrowhead Pharmaceuticals announced interim clinical data for ARO-RAGE, an investigational RNAi-based medicine for inflammatory lung diseases like asthma. The data revealed significant reductions in soluble RAGE (sRAGE) levels in both bronchoalveolar lavage fluid (BALF) and serum among healthy volunteers and asthma patients. ARO-RAGE achieved up to 88% reduction in sRAGE in asthma patients after two doses, with sustained effects supporting bi-monthly dosing. The treatment demonstrated a favorable safety profile with no serious adverse effects. Additionally, Arrowhead presented promising preclinical results for therapies targeting thymic stromal lymphopoietin (TSLP) and influenza A viruses.
Arrowhead Pharmaceuticals, Inc. reported its fiscal 2024 second quarter results, showcasing progress in its RNAi-based medicines. The company received a $50 million milestone payment, presented positive data from its plozasiran study, and initiated an Expanded Access Program. Additionally, Arrowhead strengthened its balance sheet through a stock offering. Financially, the company reported a net loss and increased cash reserves.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) received a $50 million milestone payment from Royalty Pharma plc for completing enrollment in the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen. Arrowhead stands to earn up to an additional $375 million from Amgen and $110 million from Royalty Pharma in milestone payments related to olpasiran. The rapid enrollment in the trial reflects the interest in olpasiran, developed using Arrowhead's TRiMTM technology. With three Phase 3 programs in progress, including plozasiran, Arrowhead continues to advance RNA interference therapies.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced its participation in various upcoming conferences in May 2024. The events include presentations on innovative therapies targeting different diseases like ALS, asthma, influenza, dyslipidemia, and others. Several key researchers will present the latest findings on RNA interference therapies, showcasing the company's advancements in the field.
FAQ
What is the current stock price of Arrowhead Pharma (ARWR)?
What is the market cap of Arrowhead Pharma (ARWR)?
